MedTrace Logo

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

NCT02975206 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 484

Last updated 2021-05-20

Study results available
· View outcomes & findings →

Summary

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

Conditions

Interventions

DRUG

Serlopitant High Dose

serlopitant tablets - high dose

DRUG

Placebo Oral Tablet

placebo tablet

DRUG

Serlopitant Low Dose

serlopitant tablets - low dose

Sponsors & Collaborators

  • Vyne Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Mary Spellman, MD · Vyne Therapeutics Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-01-16
Completion
2018-02-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02975206 on ClinicalTrials.gov